FrancophonIA/ELRC3.0 huggingface dataset:
English: Patients with HIV and hepatitis B or C virus co-infection Patients with chronic hepatitis B or C treated with ART are at an increased risk for severe and potentially fatal hepatic adverse reactions.
Croatian: Bolesnici koji su istodobno inficirani virusom hepatitisa B ili hepatitisa C Bolesnici s kroničnim hepatitisom B ili C koji se liječe ART-om izloženi su povećanom riziku za razvoj teških nuspojava povezanih s jetrom s potencijalno smrtnim ishodom.
English: The following adverse reactions were identified through post-marketing surveillance of raltegravir: thrombocytopenia, suicidal ideation, suicidal behaviour (particularly in patients with a pre-existing history of psychiatric illness), hepatic failure, Stevens Johnson syndrome, drug rash with eosinophilia and systemic symptoms (DRESS), rhabdomyolysis.
Croatian: Sljedeće su nuspojave otkrivene praćenjem nakon stavljanja raltegravira u promet: trombocitopenija, suicidalne ideacije, suicidalno ponašanje (osobito u bolesnika s već postojećom psihijatrijskom bolešću u anamnezi), zatajenje jetre, Stevens-Johnsonov sindrom, osip izazvan lijekom uz eozinofiliju i sustavne simptome (DRESS), rabdomioliza.
English: It contains the active substances lamivudine and raltegravir:
Croatian: Sadrži djelatne tvari lamivudin i raltegravir:
English: Depression, including suicidal ideation and behaviours, has been reported with raltegravir, particularly in patients with a pre-existing history of depression or psychiatric illness.
Croatian: Pri primjeni raltegravira prijavljena je depresija, uključujući suicidalne ideacije i ponašanja, osobito u bolesnika s depresijom ili psihijatrijskom bolešću u anamnezi.
English: Autoimmune disorders (such as Graves' disease) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment.
Croatian: U uvjetima imunološke reaktivacije prijavljeni su i autoimuni poremećaji (npr. Gravesova bolest); međutim, prijavljeno vrijeme do pojave je različito i ti se događaji mogu javiti više mjeseci nakon uvođenja liječenja.
English: There is limited information regarding the use of lamivudine and raltegravir in the elderly (see section 5.2).
Croatian: Podaci o primjeni lamivudina i raltegravira u starijih osoba su ograničeni (vidjeti dio 5.2).
English: For patients co-infected with hepatitis who are being treated with DUTREBIS and subsequently become pregnant, consideration should be given to the possibility of a recurrence of hepatitis on discontinuation of DUTREBIS.
Croatian: U bolesnica s istodobnom infekcijom hepatitisom koje se liječe lijekom DUTREBIS i u međuvremenu zatrudne mora se razmotriti mogućnost recidiva hepatitisa nakon prekida liječenja lijekom
English: • high doses of co-trimoxazole - used to treat infections.
Croatian: • visoke doze kotrimoksazola - koriste se za liječenje infekcija.
English: Discontinue DUTREBIS and other suspect agents immediately if signs or symptoms of severe skin reactions or hypersensitivity reactions develop (including, but not limited to, severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial oedema, hepatitis, eosinophilia, angioedema).
Croatian: Odmah obustavite primjenu lijeka DUTREBIS i drugih suspektnih lijekova ako se pojave znakovi ili simptomi teških kožnih reakcija ili reakcija preosjetljivosti (primjerice, ali ne i jedino, teški osip ili osip praćen vrućicom, opća malaksalost, umor, bolovi u mišićima ili zglobovima, mjehurići, oralne lezije, konjunktivitis, edem lica, hepatitis, eozinofilija, angioedem).
English: Therefore no dose adjustment of DUTREBIS is required with use of proton pump inhibitors or H2
Croatian: Stoga nije potrebno prilagođavati dozu lijeka DUTREBIS pri primjeni inhibitora protonske pumpe ili antagonista H2 receptora.
English: DUTREBIS should be used with caution in patients who have had myopathy or rhabdomyolysis in the past or have any predisposing issues including other medicinal products associated with these conditions (see section 4.8).
Croatian: DUTREBIS se mora primjenjivati uz oprez u bolesnika koji su ranije imali miopatiju ili rabdomiolizu ili imaju neki od predisponirajućih čimbenika, uključujući primjenu drugih lijekova povezanih s tim stanjima (vidjeti dio 4.8).
English: DUTREBIS is not for use in children below 6 years of age.
Croatian: DUTREBIS nije namijenjen za primjenu u djece mlađe od 6 godina.
English: In HIV-infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
Croatian: U bolesnika inficiranih HIV-om s teškim imunološkim deficitom u trenutku uvođenja kombinirane antiretrovirusne terapije može se razviti upalna reakcija na asimptomatske ili rezidualne oportunističke patogene te uzrokovati ozbiljna klinička stanja ili pogoršanje simptoma.
English: DUTREBIS should not be used in children below 6 years of age.
Croatian: DUTREBIS se ne smije primjenjivati u djece mlađe od 6 godina.
English: Raltegravir in the fixed-dose combination tablet was not bioequivalent with respect to C12, however, based on PK/PD modelling, no clinically meaningful differences in raltegravir exposure are expected following administration of the fixed-dose combination tablet compared to administration of raltegravir as a single agent.
Croatian: Raltegravir u tableti s fiksnom kombinacijom doza nije bio bioekvivalentan s obzirom na C12; međutim, na temelju farmakokinetičko-farmakodinamičkog modeliranja, ne očekuju se klinički značajne razlike u izloženosti raltegraviru nakon primjene tablete s fiksnom kombinacijom doza u odnosu na primjenu raltegravira samostalno.
English: Co-administration of DUTREBIS with high doses of co-trimoxazole for the treatment of Pneumocystis carinii pneumonia (PCP) and toxoplasmosis should be avoided.
Croatian: Mora se izbjegavati istodobna primjena lijeka DUTREBIS s visokim dozama kotrimoksazola za liječenje pneumonije izazvane s Pneumocystis carinii i toksoplazmoze.
English: Delay in stopping DUTREBIS treatment or other suspect agents after the onset of severe rash may result in a life-threatening reaction.
Croatian: Oklijevanje s obustavom primjene lijeka DUTREBIS ili drugih suspektnih lijekova nakon pojave teškog osipa može dovesti do reakcija
English: DUTREBIS is used to treat HIV (Human Immunodeficiency Virus).
Croatian: DUTREBIS se koristi za liječenje HIV-a (virusa humane imunodeficijencije).
English: It should be taken into account that raltegravir is presented for clinical use as the potassium salt.
Croatian: Treba uzeti u obzir da se u kliničkom liječenju raltegravir primjenjuje u obliku kalijeve soli.
English: DUTREBIS should not be given in patients with a creatinine clearance of <50 ml/min.
Croatian: DUTREBIS se ne smije davati bolesnicima s klirensom kreatinina od <50 ml/min.
English: Renal function should be monitored in patients more likely to have decreased renal function.
Croatian: Potrebno je pratiti funkciju bubrega u bolesnika u kojih je vjerojatnije smanjenje funkcije bubrega.
English: • blood test showing decreased count of platelets in blood (a kind of cell that helps blood clot); blood test showing reduced kidney function; increased muscle enzyme in blood; sugar present in urine; red blood cells present in urine; weight gain; increase in waist size; decreased blood protein (albumin); increase in time for blood to clot; blood test showing
Croatian: • smanjen broj krvnih pločica (stanice koje pomažu zgrušavanju krvi) u nalazima krvnih pretraga; nalazi krvnih pretraga koji ukazuju na smanjenu funkciju bubrega; povišene vrijednosti enzima iz mišića u krvi; šećer u mokraći; crvene krvne stanice u mokraći; porast tjelesne težine; povećanje opsega struka; snižene vrijednosti bjelančevina (albumina) u krvi; produljeno vrijeme zgrušavanja krvi; smanjen broj crvenih krvnih stanica u nalazima krvnih pretraga (anemija).
English: Co-administration of DUTREBIS with other agents that increase gastric pH (e.g., omeprazole and famotidine) may increase the rate of raltegravir absorption and result in increased plasma levels of raltegravir (see Table 1).
Croatian: Istodobna primjena lijeka DUTREBIS s drugim lijekovima koji povisuju želučani pH (npr. omeprazolom i famotidinom) može povećati stopu apsorpcije raltegravira i dovesti do povišenja koncentracije raltegravira u plazmi (vidjeti Tablicu 1).
English: Plasma HIV-1 RNA (log10 copies/ml), mean [range]
Croatian: HIV-1 RNK u plazmi (log10 kopija/ml), srednja vrijednost
English: A study of the pharmacokinetics of raltegravir was performed in adult patients with severe renal insufficiency.
Croatian: Ispitivanje farmakokinetike raltegravira provedeno je u odraslih bolesnika s teškom insuficijencijom bubrega.
English: The raltegravir component in DUTREBIS (300 mg raltegravir) fixed-dose combination tablet was not bioequivalent with respect to C12, however, based on PK/PD modelling, no clinically meaningful differences in raltegravir exposure are expected.
Croatian: Dokazano je da raltegravir u DUTREBIS (300 mg raltegravira) tableti s fiksnom kombinacijom doza nije bio bioekvivalentan s obzirom na C12; međutim, na temelju farmakokinetičko-farmakodinamičkog modeliranja, ne očekuju se klinički značajne razlike u izloženosti raltegraviru.
English: Co-administration of DUTREBIS with medicinal products that are known to be potent UGT1A1 inhibitors (e.g., atazanavir) may increase plasma levels of raltegravir.
Croatian: Istodobna primjena lijeka DUTREBIS s lijekovima za koje se zna da su potentni inhibitori UGT1A1 (npr. atazanavir) može povisiti koncentraciju raltegravira u plazmi.
English: If the submission of a PSUR and the update of a RMP coincide, they can be submitted at the same
Croatian: Ako se rokovi podnošenja periodičkog izvješća o neškodljivosti (PSUR) podudaraju s nadopunama Plana (RMP), dokumenti mogu biti podneseni istodobno.
English: Of the 126 patients, 96 received the recommended dose of
Croatian: Od 126 bolesnika 96 ih je primalo preporučenu dozu raltegravira.
English: Following administration of an oral dose of radiolabeled raltegravir, approximately 51 and 32 % of the dose was excreted in faeces and urine, respectively.
Croatian: Nakon peroralne primjene doze raltegravira označenog radioizotopom oko 51% doze izlučilo se fecesom, a oko 32% urinom.
English: Raltegravir is eliminated primarily by glucuronidation in the liver.
Croatian: Primarni put eliminacije raltegravira je glukuronidacija u jetri.
English: The pharmacokinetics of DUTREBIS in children under 6 years of age has not been established.
Croatian: Nije utvrđena farmakokinetika lijeka DUTREBIS u djece mlađe od 6 godina.
English: The following data are based on findings in separate studies with the individual components of DUTREBIS (lamivudine and raltegravir).
Croatian: Podaci u nastavku temelje se na rezultatima zasebnih ispitivanja pojedinačnih komponenti lijeka DUTREBIS (lamivudina i raltegravira).
English: Transmission of HIV
Croatian: Prijenos virusa HIV-a
English: No dose adjustment required for DUTREBIS or tenofovir disoproxil fumarate.
Croatian: Nije potrebno prilagođavati dozu lijeka DUTREBIS ili tenofovir dizoproksil fumarata.
English: MSD Belgium BVBA/SPRL Tél/Tel: 0800 38 693 (+32(0)27766211) dpoc_belux@merck.com
Croatian: MSD Belgium BVBA/SPRL Tél/Tel: 0800 38 693 (+32(0)27766211)
English: When DUTREBIS is administered, raltegravir is absorbed with a Tmax of approximately 1 hour in the fasted state.
Croatian: Nakon primjene lijeka DUTREBIS natašte, raltegravir se apsorbira uz tmax od približno 1 sata.
English: In some patients with advanced HIV infection and a history of opportunistic infection, signs and symptoms of inflammation from previous infections may occur soon after HIV treatment is started.
Croatian: U nekih bolesnika s uznapredovalom HIV infekcijom koji su već imali oportunističke infekcije mogu se ubrzo nakon početka liječenja HIV-a pojaviti znakovi i simptomi upale od prijašnjih infekcija.
English: A median of 4 ARTs was used in OBT.
Croatian: OBT je obuhvaćala medijan primjene 4 ART-a.
English: One patient experienced drug related laboratory abnormalities, Grade 4 AST and Grade 3 ALT, which
Croatian: U jednog su bolesnika zabilježena odstupanja laboratorijskih vrijednosti povezanih s primjenom lijeka, AST-a 4. stupnja i ALT-a 3. stupnja, koja su se smatrala ozbiljnima.
English: A carcinogenicity study of raltegravir in mice did not show any carcinogenic potential.
Croatian: U istraživanju karcinogenosti na miševima nije utvrđen kancerogeni potencijal raltegravira.
English: To monitor maternal-foetal outcomes in patients inadvertently administered DUTREBIS while pregnant, an Anti-retroviral Pregnancy Registry has been established.
Croatian: Registar trudnica koje su u trudnoći liječene antiretrovirusnim lijekovima Radi praćenja ishoda trudnoća za majku i fetus u bolesnica kojima je tijekom trudnoće nepažnjom primijenjen DUTREBIS uspostavljen je Registar trudnica koje su u trudnoći liječene antiretrovirusnim lijekovima.
English: Once absorbed the lamivudine and raltegravir distribution, metabolism, and excretion are similar to those of the reference components administered individually as described in the following paragraphs.
Croatian: Nakon što se apsorbiraju, distribucija, metabolizam i izlučivanje lamivudina i raltegravira slični su kao nakon samostalne primjene referentnih komponenata, kako je
English: Raltegravir has been studied in 126 antiretroviral treatment-experienced HIV-1 infected children and adolescents 2 through 18 years of age, in combination with other antiretroviral agents in IMPAACT P1066 (see sections 5.1 and 5.2).
Croatian: Raltegravir je, u kombinaciji s drugim antiretrovirusnim lijekovima u ispitivanju IMPAACT P1066, ispitan u 126 djece i adolescenata u dobi od 2 do 18 godina inficiranih virusom HIV-1 koji su prethodno primali antiretrovirusnu terapiju (vidjeti dijelove 5.1 i 5.2).
English: Myopathy and rhabdomyolysis have been reported.
Croatian: Prijavljene su miopatija i rabdomioliza.
English: DUTREBIS is not a cure for HIV infection.
Croatian: DUTREBIS neće izliječiti HIV infekciju.
English: Efavirenz 600 mg at bedtime (N = 282)
Croatian: Efavirenz 600 mg navečer prije spavanja (N=282)
English: Based on in vitro and in vivo studies, raltegravir is eliminated mainly by metabolism via a UGT1A1-mediated glucuronidation pathway.
Croatian: Istraživanja in vitro i in vivo pokazuju da se raltegravir eliminira uglavnom metaboliziranjem putem glukuronidacije posredovane UGT1A1.
English: • cladribine - used to treat hairy cell leukaemia.
Croatian: • kladribin - koristi se za liječenje leukemije vlasastih stanica.
English: Dizziness has been reported in some patients during treatment with regimens containing raltegravir, which may influence some patients' ability to drive and use machines (see section 4.8).
Croatian: U nekih bolesnika koji su kao dio režima liječenja primali raltegravir prijavljena je omaglica, koja može utjecati na sposobnost nekih bolesnika da upravljaju vozilima i rade sa strojevima (vidjeti
English: In addition, raltegravir inhibited viral replication in cultures of mitogen-activated human peripheral blood mononuclear cells infected with diverse, primary clinical isolates of HIV-1, including isolates from 5 non-B subtypes, and isolates resistant to reverse transcriptase inhibitors and protease inhibitors.
Croatian: Dodatno, raltegravir je inhibirao replikaciju virusa u mitogeno aktiviranim kulturama mononuklearnih stanica iz humane periferne krvi, inficiranih različitim, primarno kliničkim, izolatima virusa HIV-1, uključujući izolate
English: At 96-weeks, in treatment-experienced patients, Grade 2 or higher laboratory abnormalities that represent a worsening Grade from baseline of AST, ALT or total bilirubin occurred in 29 %, 34 % and 13 %, respectively, of co-infected subjects treated with raltegravir as compared to 11 %, 10 % and 9 % of all other subjects treated with raltegravir.
Croatian: Nakon 96 tjedana su u prethodno liječenih bolesnika odstupanja u laboratorijskim nalazima AST-a, ALT-a i ukupnog bilirubina 2. ili višeg stupnja koja su predstavljala pogoršanje u odnosu na početne vrijednosti zabilježena u 29%, 34% odnosno 13% ispitanika s istodobnom infekcijom koji su liječeni raltegravirom, u usporedbi s 11%, 10% odnosno 9% svih ostalih ispitanika liječenih raltegravirom.
English: Cases of lactic acidosis, sometimes fatal, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues (see section 4.4).
Croatian: Pri primjeni nukleozidnih analoga prijavljeni su slučajevi laktacidoze, ponekad sa smrtnim ishodom, koja je obično je bila udružena s teškom hepatomegalijom i steatozom jetre (vidjeti dio 4.4).
English: Therefore, when DUTREBIS is co-administered with calcium carbonate containing antacids no dose adjustment is required.
Croatian: Stoga pri istodobnoj primjeni lijeka DUTREBIS i antacida koji sadrže kalcijev karbonat nije potrebno prilagođavati dozu.
English: • bloating; excessive gas in the stomach or bowel; indigestion; belching
Croatian: • nadutost; previše plinova u želucu ili crijevima; probavne smetnje; podrigivanje
English: Apparent total oral clearance (Cl/F) of lamivudine decreased as creatinine clearance decreased.
Croatian: Prividan ukupni klirens lamivudina nakon peroralne primjene (Cl/F) smanjivao se sa smanjenjem klirensa kreatinina.
English: The safety and efficacy of lamivudine and raltegravir have not been established in patients with severe underlying liver disorders.
Croatian: Nisu utvrđene sigurnost i djelotvornost lamivudina i raltegravira u bolesnika s postojećim teškim poremećajima funkcije jetre.
English: Please refer to the SmPC for the individual components of DUTREBIS for dosing instructions (see section 4.4).
Croatian: Za upute o doziranju, pročitajte Sažetke opisa svojstava lijeka pojedinačnih komponenti lijeka DUTREBIS (vidjeti dio 4.4).
English: DUTREBIS should be used in combination with other active anti-retroviral therapy (ART) (see
Croatian: DUTREBIS se mora primjenjivati u kombinaciji s drugom aktivnom antiretrovirusnom terapijom (ART) (vidjeti dijelove 4.4 i 5.1).
English: The pharmacokinetics of DUTREBIS in the paediatric patient population has not been studied in clinical studies.
Croatian: U kliničkim ispitivanjima nije ispitivana farmakokinetika lijeka DUTREBIS u populaciji pedijatrijskih bolesnika.
English: Some people taking DUTREBIS or other antiretroviral medicines may have other effects show up
Croatian: U nekih osoba koje uzimaju DUTREBIS ili druge antiretrovirusne lijekove mogu se u nalazima krvnih pretraga otkriti druge promjene:
English: Table 3 Efficacy Outcome at Weeks 48 and 240
Croatian: Ishod djelotvornosti u 48. i 240. tjednu
English: Medicinal products by therapeutic area
Croatian: Lijekovi po terapijskim područjima Interakcija
English: Studies in patients with renal impairment show lamivudine elimination is affected by renal dysfunction.
Croatian: Ispitivanja u bolesnika s oštećenjem bubrega pokazuju da poremećaj funkcije bubrega utječe na eliminaciju lamivudina.
English: Similar AUC values for fed vs. fasted and somewhat lower Cmax values (23 % for raltegravir and 21 % for lamivudine) were observed with DUTREBIS.
Croatian: Uz DUTEBRIS su i nakon primjene uz obrok i nakon primjene natašte primijećene slične vrijednosti AUC-a te nešto niže vrijednosti Cmax (23% niže za raltegravir i 21% niže za lamivudin).
English: Pharmacokinetic parameters were not altered by diminishing hepatic function; therefore, no dose adjustment for lamivudine is required for patients with impaired hepatic function.
Croatian: Budući da je utvrđeno da smanjena jetrena funkcija ne utječe na farmakokinetičke parametre, nije potrebno prilagođavati dozu lamivudina u bolesnika s oštećenjem funkcije jetre.
English: The pharmacokinetic properties of lamivudine have been determined in adults with impaired hepatic function.
Croatian: Farmakokinetička svojstva lamivudina određena su u odraslih osoba s oštećenom funkcijom jetre.
English: Remember that DUTREBIS is not a cure for HIV infection.
Croatian: Zapamtite da DUTREBIS neće izliječiti HIV infekciju.
English: Administration of lamivudine in animal toxicity studies at high doses was not associated with any major organ toxicity.
Croatian: U toksikološkim ispitivanjima na životinjama lamivudin primijenjen u visokim dozama nije uzrokovao oštećenja niti jednog važnijeg organa.
English: BENCHMRK 1 and BENCHMRK 2 (multi-centre, randomised, double-blind, placebo-controlled studies) evaluated the safety and anti-retroviral activity of raltegravir 400 mg twice daily vs. placebo in a combination with optimized background therapy (OBT), in HIV-infected patients, 16 years or older, with documented resistance to at least 1 medicinal product in each of 3 classes (NRTIs, NNRTIs, PIs) of anti-retroviral therapies.
Croatian: U ispitivanjima BENCHMRK 1 i BENCHMRK 2 (multicentrična, randomizirana, dvostruko slijepa, placebom kontrolirana ispitivanja) ocjenjivale su se sigurnost i antiretrovirusna aktivnost raltegravira u dozi od 400 mg dvaput na dan naspram placeba, u kombinaciji s optimiziranom osnovnom terapijom (engl. optimised background therapy, OBT) u bolesnika inficiranih HIV-om u dobi od 16 ili više godina, a u kojih je dokumentirana rezistencija na barem 1 lijek iz svake od 3 skupine antiretrovirusnih lijekova (NRTI, NNRTI, IP).
English: Rash considered by the investigator to be drug-related occurred at similar rates.
Croatian: Stope učestalosti osipa za koje je ispitivač smatrao da su povezane s primjenom lijeka bile su slične.
English: cladribine /lamivudine
Croatian: kladribin/lamivudin
English: There have been reports of mitochondrial dysfunction in HIV-negative infants exposed in utero and/or post-natally to nucleoside reverse transcriptase inhibitors.
Croatian: Prijavljeni su slučajevi disfunkcije mitohondrija u HIV-negativne dojenčadi koja su bila izložena nukleozidnim inhibitorima reverzne transkriptaze in utero i/ili po rođenju.
English: The safety profile of DUTREBIS is based on the safety data from the individual components of DUTREBIS (lamivudine
Croatian: Sigurnosni profil lijeka DUTREBIS temelji se na podacima o sigurnosti primjene pojedinačnih komponenti lijeka DUTREBIS
English: A connection between visceral lipomatosis and protease inhibitors (PIs) and lipoatrophy and NRTIs has been hypothesised.
Croatian: Postoji hipoteza o povezanosti visceralne lipomatoze i primjene inhibitora proteaze (IP) te lipoatrofije i primjene NRTI-ja.
English: Very rare (may affect up to 1 in 10,000 people)
Croatian: Vrlo rijetke (mogu se javiti u do 1 na 10 000 osoba):
English: There were no clinically important pharmacokinetic differences due to gender, race or body mass index (BMI) for
Croatian: Nije bilo klinički važnih razlika u farmakokinetici raltegravira s obzirom na spol, rasu ili indeks tjelesne mase u odraslih.
English: DUTREBIS should not be used in children below 6 years of age or in patients weighing less than 30 kg due to weight based dosing requirements in this patient population.
Croatian: DUTREBIS se ne smije primjenjivati u djece mlađe od 6 godina niti u bolesnika tjelesne težine manje od 30 kg jer se u toj populaciji bolesnika doziranje treba odrediti na temelju tjelesne
English: • feeling or being sick (nausea or vomiting), diarrhoea, stomach pain
Croatian: • mučnina ili povraćanje, proljev, bol u trbuhu
English: • acne; unusual hair loss or thinning; redness of skin; unusual distribution of fat on the body, this may include loss of fat from legs, arms, and face, and increase in abdomen fat; excessive sweating; night sweats; thickening and itching of the skin due to repeated
Croatian: • akne; neuobičajeno opadanje ili prorjeđivanje kose; crvenilo kože; promjena u raspodjeli masnog tkiva u tijelu, što može uključivati gubitak masnog tkiva na nogama, rukama i licu i nakupljanje masti na trbuhu; pojačano znojenje; noćno znojenje; zadebljanje i svrbež kože zbog učestalog češanja; oštećenja kože; suha koža